A Phase 1 interventional study of AT-587 and Placebo in Hepatitis E, sponsored by Atea Pharmaceuticals, Inc.. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Atea Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects
A Phase 1, First-in-Human (FIH), Single-center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of AT-587 in Healthy Adult Participants
37 studies on the registry are indexed under Hepatitis E; 9 are open to participants now.
This study's planned enrollment of 62 is below the median of 330 across 26 interventional studies indexed under Hepatitis E.
Browse Hepatitis E studies →Atea Pharmaceuticals, Inc. is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 4 (16%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AT-587 administered orally, dose 1 on Day 1
Drug: AT-587
Matching placebo dose 1 administered orally on Day 1
Other: Placebo
AT-587 administrated orally, dose 2 on Day 1 and Day 7
Drug: AT-587
Matching placebo dose 2 administered orally on Day 1 and Day 7
Other: Placebo
AT-587 administered orally, dose 3 on Day 1
Drug: AT-587
Matching placebo dose 3 administered orally on Day 1
Other: Placebo
AT-587 administered orally, dose 4 on Day 1
Drug: AT-587
Matching placebo dose 4 administered orally on Day 1
Other: Placebo
AT-587 - administered orally, dose 5 (QD) for 7 days
Drug: AT-587
Matching placebo dose 5 administered orally once daily (QD) for 7 days
Other: Placebo
AT-587 administered orally, dose 6 daily split (BID) for 7 days
Drug: AT-587
Matching placebo administered orally dose 6 daily split (BID) for 7 days
Other: Placebo
AT-587 administered orally, dose 7 (QD) or split (BID) for 7 days
Drug: AT-587
Matching placebo administered orally, dose 7 daily (QD) or split (BID) for 7 days
Other: Placebo
Parallel Assignment
Parallel Assignment
Proportions (active vs. Placebo) of subjects experiencing treatment-emergent adverse events
Time frame: Day 1 up to Day 13
Pharmacokinetics (PK) of AT-587 (Cmax)
Maximum plasma concentration (Cmax)
Time frame: Day 1 up to Day 13
Pharmacokinetics (PK) of AT-587 (AUC)
Area under the concentration-time curve (AUC)
Time frame: Day 1 up to Day 13
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.